Ruizhi Wang

Dr. Ruizhi Wang is a Chinese-origin scientist-entrepreneur and the Founder and CEO of Abselion, a Cambridge-based life sciences technology company simplifying protein quantification for biopharmaceutical research and development. He holds a PhD from the University of Cambridge and MSc and BSc degrees from ETH Zurich, combining deep expertise in electrochemistry, biosensing, nanotechnology, and data science. A Royal Academy of Engineering Enterprise Fellow and recipient of recognition from the Royal Society of Chemistry, the Merck Group, and Cambridge University Entrepreneurs, Wang founded Abselion in 2018 — originally under the name HexagonFab — from a laboratory corner at the University of Cambridge.

His motivation was straightforward: scientists making critical decisions about therapeutic development were forced to wait days for protein data that should be available in minutes. Abselion's flagship Amperia system, built on proprietary Redox Electrochemical Detection (RED) technology, allows scientists to quantify antibodies, AAVs, and other proteins directly from crude samples in as little as one minute — at-line, at any bench or bioreactor, without the complexity of traditional methods. The platform is specifically designed to accelerate bioprocess development and manufacturing for biologics, gene therapies, and viral vectors. Wang has co-authored over 20 scientific publications with more than 700 citations.

In December 2024, Abselion raised £6.6 million in a Series A round led by M Ventures, the strategic corporate VC arm of Merck, with participation from BioProcess 360 Partners, Untitled Ventures, BGF, and R42. The funding is being used to commercialise the Amperia system globally, including the establishment of a US subsidiary at MIT's The Engine in Cambridge, Massachusetts. Abselion has been adopted by NHS Blood and Transplant's Clinical Biotechnology Centre, among other leading research institutions, as it scales into the £100 billion+ global health life sciences market.